Neuberger Berman Group’s TG Therapeutics TGTX Stock Holding History

Neuberger Berman Group’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$383K	Buy	11,523 +1,831	+19%	+$54.6K	﹤0.01%	1733
2025 Q4	$289K	Buy	9,692 +2,450	+34%	+$80K	﹤0.01%	1816
2025 Q3	$262K	Sell	7,242 -834	-10%	-$27.5K	﹤0.01%	1804
2025 Q2	$291K	Buy	8,076 +158	+2%	+$5.88K	﹤0.01%	1741
2025 Q1	$312K	Buy	+7,918	New	+$266K	﹤0.01%	1686
2013 Q4	–	Sell	-126,200	Closed	-$636K	–	1665
2013 Q3	$636K	Buy	+126,200	New	+$772K	﹤0.01%	1260

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Neuberger Berman Group's TGTX Position: Q1 2026 in Review

Neuberger Berman Group increased its TG Therapeutics (TGTX) stake by 19% in Q1 2026, buying an estimated $54.6K and bringing the position to 11,523 shares worth $383K. The position accounts for ﹤0.01% of the portfolio, ranked #1733.

Neuberger Berman Group first reported a position in TGTX in Q3 2013 and has held it in 6 quarters since. The position peaked at $636K in Q3 2013. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

Neuberger Berman Group held 11,523 shares of TG Therapeutics worth $383K as of Q1 2026.
Neuberger Berman Group bought 1,831 TG Therapeutics shares in Q1 2026, an estimated $54.6K.
TG Therapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q1 2026, its #1733 holding.
Neuberger Berman Group first reported a position in TG Therapeutics in Q3 2013 and has held it in 6 quarters since.
Neuberger Berman Group's TG Therapeutics position peaked at $636K in Q3 2013.
363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.